RT Journal Article
SR Electronic
T1 Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4913
OP 4918
DO 10.21873/anticanres.12807
VO 38
IS 8
A1 ANDREA SBRANA
A1 ELISA BIASCO
A1 FEDERICO PAOLIERI
A1 ERICA PALESANDRO
A1 CLAUDIA CASERTA
A1 ROBERTO IACOVELLI
A1 BEATRICE DETTI
A1 DANIELE SANTINI
A1 ALESSANDRA MOSCA
A1 FRANCO MORELLI
A1 GIUSEPPE FORNARINI
A1 UGO DE GIORGI
A1 CRISTINA MASINI
A1 LUCA GALLI
YR 2018
UL http://ar.iiarjournals.org/content/38/8/4913.abstract
AB Background/Aim: The specific characteristics of patients who are most likely to benefit from pazopanib therapy are still uncertain. We report on the results of an Italian multicenter, retrospective analysis investigating the factors associated with longer response to first-line pazopanib in patients with metastatic renal cell carcinoma. Patients and Methods: Adult patients were considered if they had received treatment with pazopanib (800 mg/day) for >12 months in the first-line setting. Results: In total, 112 patients were evaluated. Median duration of pazopanib treatment was 22.6 months (IQR 17.8 months). Median PFS was 22.6 months (95%CI= 20.2-25.0). Eighty-three patients (74.1%) had a PFS ≥18 months. Median OS was 32.9 months (95%CI=30.2-35.6). At statistical analysis, only PS score (1+ vs. 0) was significantly associated with PFS (HR=1.76; 95%CI=1.02-3.05; p=0.04). Conclusion: Pazopanib therapy may be suitable for all patients with mRCC, and especially in those with PS 0.